Z Squared Inc. (ZSQR): Nasdaq/NYSE listing notice — Coeptis Therapeutics receives Nasdaq deficiency notice for MVLS below $50M minimum

Z Squared Inc.

Nasdaq letter dated Dec. 22, 2022; MVLS below $50M for 30 consecutive business days.
Company has 180 calendar days, until June 20, 2023, to regain compliance.
If MVLS closes at $50M+ for 10 consecutive business days before deadline, compliance will be achieved.
No immediate effect on listing or trading of COEP common stock or warrants.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 1.0

Z Squared Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(3)(A), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(3)(A), 5810(c)(3)(C)

Exact text from the filing

December 22, 2022, the Company received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (“MVLS”) had been below the $50 million minimum requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(3)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until June 20, 2023, to regain compliance. The letter states that

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Z Squared Inc. filing history →

Source: SEC EDGAR

accession 0001683168-22-008676

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.